Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BBIO 
BridgeBio Pharma Inc (BBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $59.16
1 Year Target Price $59.16
| 10 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.37% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.52B USD | Price to earnings Ratio - | 1Y Target Price 59.16 |
Price to earnings Ratio - | 1Y Target Price 59.16 | ||
Volume (30-day avg) 19 | Beta 1.1 | 52 Weeks Range 21.72 - 45.48 | Updated Date 06/30/2025 |
52 Weeks Range 21.72 - 45.48 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -89% |
Management Effectiveness
Return on Assets (TTM) -48.27% | Return on Equity (TTM) -1789.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9834748695 | Price to Sales(TTM) 66.85 |
Enterprise Value 9834748695 | Price to Sales(TTM) 66.85 | ||
Enterprise Value to Revenue 77.19 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 189880992 | Shares Floating 146361958 |
Shares Outstanding 189880992 | Shares Floating 146361958 | ||
Percent Insiders 4.97 | Percent Institutions 98.14 |
Analyst Ratings
Rating 4 | Target Price 59.16 | Buy 6 | Strong Buy 10 |
Buy 6 | Strong Buy 10 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BridgeBio Pharma Inc
Company Overview
History and Background
BridgeBio Pharma, Inc. was founded in 2015. It focuses on developing therapies for genetic diseases and cancers. It has acquired or partnered with various biotech companies to build its pipeline.
Core Business Areas
- Drug Discovery and Development: Focused on identifying and developing therapies for genetically driven diseases.
Leadership and Structure
Neil Kumar is the CEO. The company operates with a decentralized structure, managing a portfolio of subsidiary companies focused on specific therapeutic areas.
Top Products and Market Share
Key Offerings
- Nulibry (fosdenopterin): Used for the treatment of Molybdenum Cofactor Deficiency Type A. This is a niche market, and market share data is limited. Competitors are primarily other companies researching treatments for rare genetic disorders. Revenue data is not publicly available with specific granularity. Competitors include companies developing similar treatments for rare metabolic disorders.
- Truseltiq (infigratinib): Treats FGFR2-fusion cholangiocarcinoma. Limited market share data available; the competitive landscape includes other targeted cancer therapies. Competitors include other pharmaceutical companies developing kinase inhibitors. Revenue data is not publicly available with specific granularity.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies. Growing demand for personalized medicine is a key trend.
Positioning
BridgeBio is positioned as a developer of therapies for genetically driven diseases. Its competitive advantage lies in its decentralized model and diverse pipeline.
Total Addressable Market (TAM)
The TAM for genetically driven diseases is very large and continues to grow with advances in genetic diagnosis, but varies greatly depending on the specific disease. BridgeBio's position within this TAM depends on the success of its pipeline and commercialized products.
Upturn SWOT Analysis
Strengths
- Diverse pipeline targeting multiple genetic diseases
- Decentralized operational model fostering innovation
- Strong partnerships with academic institutions and biotech companies
Weaknesses
- High R&D costs and development risks
- Reliance on regulatory approvals and market access
- Relatively young company with limited commercial track record
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions of complementary technologies
- Collaboration with larger pharmaceutical companies for commercialization
Threats
- Competition from established pharmaceutical companies
- Patent expirations and generic entry
- Unfavorable regulatory changes
Competitors and Market Share
Key Competitors
- REGN
- VRTX
- BLUE
Competitive Landscape
BridgeBio faces competition from both large pharmaceutical companies and smaller biotech firms. Its decentralized model aims to give it an edge in discovering and developing novel therapies.
Major Acquisitions
PellePharm
- Year: 2018
- Acquisition Price (USD millions): 76
- Strategic Rationale: Added a late-stage clinical program for Gorlin Syndrome to BridgeBio's pipeline.
Growth Trajectory and Initiatives
Historical Growth: BridgeBio has grown through acquisitions and pipeline development since its founding.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals.
Recent Initiatives: Focus on advancing key pipeline assets and securing regulatory approvals.
Summary
BridgeBio Pharma is a company focused on developing therapies for genetic diseases and cancers. Its decentralized model allows for focused innovation but also introduces R&D risks. Regulatory approval and competition are key challenges. Future growth depends on pipeline success and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Publicly available information
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BridgeBio Pharma Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Director Dr. Neil Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 725 | Website https://bridgebio.com |
Full time employees 725 | Website https://bridgebio.com | ||
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.